ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Consensus Rating of "Hold" by Brokerages

Key Points

• Analysts give ARS Pharmaceuticals a consensus "Hold" rating from five covering firms (1 sell, 1 hold, 3 buy) with an average 12‑month price target of $28.25.
• SPRY trades around $8.56 with a market cap near $850 million, a 12‑month range of $6.66–$18.90, and a negative P/E of -4.89; its 50‑ and 200‑day moving averages are about $8.41 and $9.38 respectively.
• Most recent quarter: EPS of -$0.42 (in line with estimates) and revenue of $28.09M (beat); the company remains unprofitable (negative ROE and a -203% net margin) and sell‑side analysts forecast about -1.54 EPS for the current fiscal year.

Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) have earned a consensus recommendation of "Hold" from the five analysts that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $28.25.

A number of equities research analysts recently weighed in on the company. Northland Securities assumed coverage on ARS Pharmaceuticals in a research report on Thursday, April 9th. They set an "outperform" rating and a $25.00 price objective on the stock. Weiss Ratings lowered ARS Pharmaceuticals from a "sell (d)" rating to a "sell (d-)" rating in a research report on Friday, April 24th. Zacks Research upgraded ARS Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research report on Wednesday, February 25th. Finally, Leerink Partners set a $26.00 target price on ARS Pharmaceuticals and gave the stock an "outperform" rating in a report on Tuesday, March 10th.

ARS Pharmaceuticals Stock Performance

Shares of SPRY stock opened at $8.56 on Monday. The firm has a market capitalization of $849.98 million, a P/E ratio of -4.89 and a beta of 0.93. ARS Pharmaceuticals has a twelve month low of $6.66 and a twelve month high of $18.90. The company has a quick ratio of 7.06, a current ratio of 7.28 and a debt-to-equity ratio of 1.47. The stock's fifty day simple moving average is $8.41 and its 200 day simple moving average is $9.38.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last issued its quarterly earnings data on Monday, March 9th. The company reported ($0.42) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.42). The business had revenue of $28.09 million for the quarter, compared to analyst estimates of $25.58 million. ARS Pharmaceuticals had a negative return on equity of 100.29% and a negative net margin of 203.25%. As a group, sell-side analysts predict that ARS Pharmaceuticals will post -1.54 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. General American Investors Co. Inc. lifted its holdings in ARS Pharmaceuticals by 29.9% during the 1st quarter. General American Investors Co. Inc. now owns 727,154 shares of the company's stock worth $5,839,000 after buying an additional 167,195 shares during the period. Kestra Advisory Services LLC lifted its holdings in ARS Pharmaceuticals by 1,079.3% during the 1st quarter. Kestra Advisory Services LLC now owns 40,920 shares of the company's stock worth $329,000 after buying an additional 37,450 shares during the period. Y Intercept Hong Kong Ltd acquired a new position in ARS Pharmaceuticals during the 1st quarter worth about $128,000. Janney Montgomery Scott LLC lifted its holdings in ARS Pharmaceuticals by 56.6% during the 1st quarter. Janney Montgomery Scott LLC now owns 2,016,464 shares of the company's stock worth $16,192,000 after buying an additional 728,632 shares during the period. Finally, Creek Drive Management Group LLC acquired a new position in ARS Pharmaceuticals during the 4th quarter worth about $3,447,000. 68.16% of the stock is owned by institutional investors and hedge funds.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc was founded in 2015 and is headquartered in San Diego, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.